BioSpace News Archive

AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the third quarter ended September 30, 2021 and provides a business update.

ImmaticsN.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported its financial results for the quarter ended September 30, 2021, and provided a business update on its progress over the reporting period.

Imara Inc. (Nasdaq: IMRA), today announced data from a pre-specified interim analysis from its ongoing Forte Phase 2b clinical trial of tovinontrine (IMR-687) in transfusion-dependent subjects (TDT) with beta-thalassemia.

Vigeo Therapeutics today announced new clinical data from its Phase 1/2 expansion study evaluating the single-agent activity of VT1021 in subjects with recurrent glioblastoma (rGBM).

HotSpot Therapeutics, Inc. today announced that company leadership will deliver a corporate overview at the Piper Sandler 33rd Annual Healthcare Conference

PureTech Announces Publication of Phase 1 Results for LYT-100 in the Journal Clinical Pharmacology in Drug Development and Provides Timing Updates

Amcyte Pharma, a Seattle-based company dedicated to the development of novel pharmaceutical products in immunology, announced the U.S. launch of its Nasitrol® nasal spray for sinus irrigation.

Viz.ai - the world leader in AI-driven intelligent care coordination, today announced the U.S. commercial launch of its AI-powered modules for pulmonary embolism and aortic disease.

Live moderated video webcast discussion among members of management on Thursday, November 18th at 9:00 AM ET

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced that it will be presenting positive results from a Phase 2a clinical study of the company’s lead drug candidate, STP705, for treatment of squamous cell skin cancer in situ at the 2021 TIDES Europe event.